| Patients (n = 141) | Control subjects (n = 141) | p Values |
---|---|---|---|
Age, years | 54 (45–61) | 54 (45–61) | 0.96 |
Women | 114 (80.9) | 114 (80.9) | 1.0 |
Disease duration, years | 6.8 (3.0–14.9) |  |  |
RF-positive | 100 (70.9) | Â | Â |
Anti-CCP-positive | 109 (77.3) | Â | Â |
Using methotrexate | 109 (77.3) | Â | Â |
Using prednisolone | 78 (55.3) | Â | Â |
Biologic DMARD at inclusion | |||
 Infliximab | 13 (9.2) |  |  |
 Etanercept | 56 (39.7) |  |  |
 Adalimumab | 6 (4.3) |  |  |
 Golimumab | 8 (5.7) |  |  |
 Certolizumab | 11 (7.8) |  |  |
 Rituximab | 32 (22.7) |  |  |
 Abatacept | 3 (2.1) |  |  |
 Tocilizumab | 12 (8.5) |  |  |
Patient’s global VAS, 0–100 | 46 (20–67) |  |  |
Assessor’s global VAS, 0–100 | 27 (18–38) |  |  |
Number of tender joints (of 32) | 4 (2–11) |  |  |
Number of swollen joints (of 32) | 6 (3–11) |  |  |
DAS28(ESR) | 4.4 (1.4)a | Â | Â |
Sum GS US score | 27 (17–43) |  |  |
Sum PD US score | 11 (4–24) |  |  |
ESR, mm/h | 22 (11–35) |  |  |
CRP, mg/L | 6 (2–12) |  |  |
Calprotectin, ng/ml | 1149 (698–1949) | 560 (412–796)b | <0.001 |
S100A12, ng/ml | 275 (142–463) | 129 (75–222) | <0.001 |
IL-6, pg/ml | 5.2 (2.1–10.8) | 0.9 (0.2–1.6) | <0.001 |
VEGF, pg/ml | 80.8 (42.8–161.8) | 67.5 (45.6–108.0) | <0.08 |